Finance

Lists
NOVA:FRA
Novo Nordisk A/S
43,44 €
-0,73%
(-0,32) 1D
28-июл., 08:01:11 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for NOVA...
Open
43,44 €
High
43,44 €
Low
43,44 €
Mkt. cap
168,50 млд
Avg. vol.
1,88 миң
Volume
0,00
52-wk high
62,70 €
52-wk low
30,45 €
No. of employees
68 миң
Open
43,44 €
High
43,44 €
Low
43,44 €
Mkt. cap
168,50 млд
Avg. vol.
1,88 миң
Volume
0,00
52-wk high
62,70 €
52-wk low
30,45 €
No. of employees
68 миң
News stories
From sources across the web
Profile
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority of its voting shares. Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices. Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations. The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company in Denmark. Wikipedia
About Novo Nordisk A/S
CEOMaziar Mike Doustdar
Employees67,9 миң
Founded1923-ж., 21-дек.
HeadquartersBagsværd, Capital Region of Denmark, Дания
SectorPharmaceutical industry
Websitenovonordisk.com
Previous reportsAll values in DKK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in DKK
2025-ж. июн.
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
Revenue
76,86 млд
74,98 млд
79,14 млд
96,82 млд
Cost of goods sold
12,85 млд
14,47 млд
14,17 млд
13,60 млд
Cost of revenue
12,85 млд
14,47 млд
14,17 млд
13,60 млд
Research and development expenses
11,69 млд
11,49 млд
12,67 млд
10,28 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
18,85 млд
15,76 млд
17,14 млд
13,22 млд
Operating expense
30,56 млд
27,25 млд
29,73 млд
23,61 млд
Total operating expenses
43,41 млд
41,72 млд
43,90 млд
37,20 млд
Operating income
33,45 млд
33,25 млд
35,24 млд
59,62 млд
Other non operating income
-
1,53 млд
-241,00 млн
-
EBT including unusual items
33,80 млд
25,52 млд
34,18 млд
62,17 млд
EBT excluding unusual items
33,80 млд
35,09 млд
37,62 млд
62,17 млд
Income tax expense
7,30 млд
5,51 млд
7,29 млд
13,62 млд
Effective tax rate
21,60%
21,60%
21,34%
21,90%
Other operating expenses
23,00 млн
-
-81,00 млн
106,00 млн
Net income
26,50 млд
20,01 млд
26,89 млд
48,56 млд
Net profit margin
34,48%
26,68%
33,98%
50,15%
Earnings per share
5,96
4,50
6,04
6,63
Interest and investment income
5,31 млд
307,00 млн
4,41 млд
-
Interest expense
-4,96 млд
-
-4,97 млд
-
Net interest expenses
356,00 млн
307,00 млн
-560,00 млн
-
Depreciation and amortization charges
-
-
-
-
EBITDA
37,65 млд
36,49 млд
36,66 млд
63,13 млд
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer